



Updated Monthly

October 10, 2024

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:





Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

October 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Amyotrophic Lateral Sclerosis	2
Artificial Intelligence & Machine Learning	2
Biomedical Research.....	3
Cancer	4
Central Nervous System	5
Chronic Pain & Pain Management	6
Cognitive and Brain Health.....	6
Communication Disorders.....	7
Cybersecurity.....	7
Endocrine & Metabolic Disease	7
Energy Science	8
Genomics	8
Health IT & Data.....	9
HIV/AIDS	9
Medical Countermeasures.....	10
Mental Health.....	10
Microbiome Research.....	11
Rare Diseases	11
Regulatory Science	11

Small Business Development	12
Substance Use Disorder	12
Therapeutics.....	14
Vision Health	14

Recurring Opportunities

Advanced Research Projects Agency for Health	15
Air Force	16
Army.....	16
BARDA	18
DARPA	18
Defense Threat Reduction Agency	19
Department of Energy.....	20
National Science Foundation	20
Navy	20
Office of the Undersecretary of Defense.....	21

GBG Acronyms	22
---------------------------	-----------



October 17, 2024 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EDT (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

BARDA Innovation Symposium: G2G is planning to attend the November 6 event to connect with government agencies and strategic partners about medical countermeasures. Will we see you there?

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AMYOTROPHIC LATERAL SCLEROSIS (1)		
1.	ALS Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH/NINDS/OD) RFA-NS-25-024	This NOFO aims to encourage grant applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-024.html	Dependent upon proposal, for up to 4 years	Letter of intent: 12/24/24 Proposal: 1/24/25
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (10)		
2.	Forecast: Computational ADME Tox AnaLYsis for Safer Therapeutics (CATALYST) (ARPA-H) ARPA-H-SN-24-114	The goal of the CATALYST program is to develop AI/ML-enabled in silico human physiology modeling platforms for ADME-Tox simulation to replace the poorly predictive IND/IND-enabling preclinical animal studies currently used. By leveraging innovation within the areas of large-scale data mining, AI/ML predictive analytics, novel high-throughput living systems instrumentation, and simulation-based whole human physiology modeling, CATALYST will create new tools to replace the current approaches that fail to fully recreate human physiology. https://sam.gov/opp/2eecb002d9d54533aae6cb7867af28d6/view https://solutions.arpa-h.gov/Events/CATALYST/	TBD	Estimated post date: 10/15/24 Proposers' Day: 10/29/24 Cincinnati, OH
3.	Strategic Catalyst Announcement for AI-BTO (DoD/DARPA) DARPA-SCA-24-01	DARPA's BTO wishes to catalyze future efforts in the topics of Prediction and Health; Autonomous Science; Simulation; Biomanufacturing and Synthetic Biology; Challenges with Scale; and Frontier topics through the generation and/or processing of data sets. https://sam.gov/opp/ad2f1fffd55e4239880e97d3642fd3ec/view	Up to \$300,000	White paper: 10/15/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
4.	NOSI: Training Program in Application of Artificial Intelligence in Development of Treatment for Substance Use Disorders (NIH/NIDA) NOT-DA-26-004	The purpose of this NOSI, with 23 linked grants, is to support workforce development and training in AI/ML to grow new generation of data scientists and promote data science literacy among researchers developing treatments for SUDs. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-26-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/28
5.	NOSI: Application of Artificial Intelligence in Treatment Development for Substance Use Disorders (NIH/NIDA) NOT-DA-26-005	The purpose of this NOSI, with 7 linked grants, is to elicit projects that would leverage the power of generative AI/ML and predictive models to accelerate medication discovery and development for treatment of SUDs while reducing the risk of failure. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-26-005.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/28
		BIOMEDICAL RESEARCH (6)		
6.	NOSI: Quantum Sensing in Biomedical Applications (SBIR/STTR) (NIH) NOT-EY-24-014	This NOSI, with 4 linked grants, intends to solicit applications proposing to advance research activities relevant to quantum sensing in biomedical and clinical research and application. The purpose of this NOSI is to support small businesses for stimulation of technological innovation in quantum sensing. https://grants.nih.gov/grants/guide/notice-files/NOT-EY-24-014.html	Up to \$306,872, for up to 1 year (Phase I) Up to \$2,045,816, for up to 2 years (Phase II) Certain topics may exceed these amounts	Multiple deadlines; NOSI open through 1/26/27
7.	NIH Quantum Sensing Technology Challenge (NIH/NCATS)	This Challenge aims to address key subject areas by incentivizing multidisciplinary teams to work together to apply emerging quantum-enabled sensing approaches to biomedical research and clinical applications to broaden current capabilities in areas such as early detection, diagnostics, and therapeutic development. The three areas of interest for the NIH Quantum Sensing Technology challenge are: Quantum-enabled Approaches to Advance Biomedical Applications; Quantum-enabled Approaches for Early Detection and Diagnostics; Quantum-enabled Sensing and Imaging Devices for Diagnostics and Monitoring. https://www.challenge.gov/?challenge=niH-quantum-sensing-technology-challenge	Total prizes of \$1.6 million	Proposal: 4/4/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
8.	NIH Quantum Computing Challenge (NIH/NCATS)	This Challenge seeks to adopt, optimize, and deploy existing quantum algorithms or develop new quantum algorithms for biomedical problems, leading to a set of transformative solutions. The three areas of interest include: Quantum Algorithms for Drug Discovery; Quantum Algorithms for Clinical Risk Predictions, Diagnosis, and Therapeutics; Quantum Algorithms for Biomedical Imaging and Genomic Data Analysis. https://www.challenge.gov/?challenge=nih-quantum-computing-challenge	Total prizes of \$1.3 million	Proposal: 2/21/25
		CANCER (6)		
9.	FY24 DOD Glioblastoma Research Program (GBMRP) (DoD/CDMRP) HT942524GBMRPHDA (HDA) HT942524GBMRPRDA (RDA)	Two awards are posted: Hypothesis Development Award and Resource Development Award. The HDA supports the exploration of highly innovative, untested, exploratory, high-risk/potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the Focus Areas: Drug Delivery and Biomarkers. The RDA supports product-driven effort focused on the advancement of preclinical model systems that need further development, characterization, validation, or standardization. https://cdmrp.health.mil/funding/gbmrp	Up to \$500,000, for up to 3 years Dependent upon award mechanism	Pre-application: 11/6/24 Proposal: 11/20/24
10.	Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed) (NIH/NCI) RFA-CA-24-036	This NOFO will establish a CIP-Net Data and Resource Coordinating Center (CIP-Net DRCC). The CIP-Net aims to be an agile and effective network to undertake collaborative research focusing on cancer immunoprevention research. The CIP-Net DRCC will provide overall data and resource coordination, support, and facilitate collaboration across CIP-Net. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-036.html	Up to \$499,999 per year, for up to 5 years	Letter of intent: 11/2/24 Proposal: 12/2/24
11.	Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening and Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required) (NIH/NCI) RFA-CA-25-009 RFA-CA-25-010	These NOFOs invite proposals for Research Projects to advance the science of scale-up and sustainment of lung cancer screening (LCS) for populations at high risk for lung cancer and tobacco use treatment (TUT) for cancer survivors. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-009.html https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-010.html	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$850,000 per year, for up to 4 (UH3)	Letter of intent: 11/6/24 Proposal: 12/6/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
12.	Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-25-013	NCI intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-013.html	Up to \$250,000 per year, for up to 3 years (UG3) Up to \$400,000 per year, for up to 2 years (UH3)	Letter of intent: 5/13/25 Proposal: 6/13/25
		CENTRAL NERVOUS SYSTEM (7)		
13.	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3/U44 Clinical Trial Optional) (NIH) PAR-24-293 (UG3/UH3) PAR-24-294 (U44)	These NOFOs provide funding, resources, and expertise to accelerate the development of diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities — for the treatment of nervous and neuromuscular system disorders. https://grants.nih.gov/grants/guide/pa-files/PAR-24-293.html (UG3/UH3) https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html (U44)	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 8/18/27
14.	Analytical and Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) (NIH/NINDS) PAR-25-050 PAR-25-055	These NOFOs are intended to address the gap in biomarker validation by encouraging rigorous analytical and clinical validation of the biomarker detection method for one or two specified context(s) of use. https://grants.nih.gov/grants/guide/pa-files/PAR-25-050.html https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 6/22/26
15.	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (NIH) PAR-25-051	The BPN invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. https://grants.nih.gov/grants/guide/pa-files/PAR-25-051.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 8/18/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CENTRAL NERVOUS SYSTEM		
16.	BRAIN Initiative: Optimization of Instrumentation and Device Technologies; and New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (U01/R01 Clinical Trial Not Allowed) (NIH) RFA-NS-25-017 (U01) RFA-NS-25-018 (R01)	These NOFOs seek applications to optimize instrumentation and device technologies; and proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and to enable transformative understanding of dynamic signaling in the central nervous system. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-017.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-018.html (R01)	Dependent upon proposal, for up to 4 years	Multiple deadlines; NOFOs open through 1/20/26
		CHRONIC PAIN & PAIN MANAGEMENT (1)		
17.	HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional) (NIH) RFA-NS-25-020	The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-020.html	Up to \$650,000 per year, for up to 5 years	Proposal: 2/6/25
		COGNITIVE AND BRAIN HEALTH (4)		
18.	Investigating how Neurological Systems Process Information in REality (INSPIRE) (DoD/DARPA) DARPA-EA-24-01-04	INSPIRE aims to explore new fundamental theories of how neurological systems may store and process information, which could inform the next generation of neurotechnologies and tools for accurately and precisely measuring neural function. All performers should address the overarching goal of discovering new fundamental theories in neuroscience with the potential for further foundational insights or development of novel technologies. https://sam.gov/opp/bea1885eeb3b44c1b8b4fee15f2fd43f/view https://sam.gov/opp/79488482aac8482d90e144029c3fb58e/view	Up to \$300,000	Webinar: 10/24/24 Proposal: 1/31/25
19.	NOSI: The Role of the Immune System in Aging Brain and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (NIH/NIA/NIAID) NOT-AG-24-010	The goal of this NOSI is to explore the role of the adaptive immune system and innate immune system and their cross-talk in the etiology of AD/ADRD. This NOSI solicits human subjects and animal research across a broad range of topics and laboratory models. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-010.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 12/30/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
20.	BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) (NIH) RFA-MH-26-120	The reagents to be distributed will first be developed in separately supported reagent design and development projects for brain cell type-specific access across vertebrate species in the BRAIN Initiative Armamentarium project. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-26-120.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 6/15/27
		COMMUNICATION DISORDERS (3)		
21.	NOSI: Developing and Evaluating Evidence-Based Practice for Users of Augmentative and Alternative Communication (AAC) (NIH/NIDCD) NOT-DC-24-041	The purpose of this NOSI is to encourage those with expertise in communication disorders to pursue research in collaboration with users of augmentative and alternative communication (AAC) using one of two approaches: (1) community-engaged research or (2) user-centered design. Both of these strategies include AAC users and their families/caregivers through the process. https://grants.nih.gov/grants/guide/notice-files/NOT-DC-24-041.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 2/3/28
		CYBERSECURITY (1)		
22.	Universal PatchinG and Remediation for Autonomous DEfense (UPGRADE) Virtual Proposers' Day (ARPA-H) ARPA-H-MAI-24-01-05	UPGRADE aims to fund the creation of vulnerability mitigation tools that act as a force multiplier for hospital IT/cybersecurity teams, dramatically advancing hospitals' capacities to understand, source, plan, and deploy security upgrades for connected hospital equipment. https://sam.gov/opp/6378f98590ae419f9f5aa78a08fed520/view	Dependent upon proposal and award mechanism	Proposal date: 10/15/24
		ENDOCRINE & METABOLIC DISEASE (4)		
23.	NIDDK Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases (NIH/NICHD) RFA-DK-23-017_RFA-DK-23-018	The NIDDK seeks industry collaborators to provide novel therapeutic agents, diagnostic markers, biomarkers and devices for use in NIH-sponsored multi-center clinical trials and ancillary studies in patients with childhood cholestatic liver diseases, including biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis; and the liver disease related complications emanating from these diseases. https://sam.gov/opp/c7b47e26151e40f38804ba34321b7179/view	N/A	Proposal: 5/31/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
24.	Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-25-022	This NOFO requests applications for Recruitment Sites (RS) to enroll adult and/or pediatric patients with T1D with, or at high risk of, diabetic nephropathy into a longitudinal cohort study and perform protocol-based research kidney biopsies. These T1D RS will leverage and expand the existing resources of the Kidney Precision Medicine Project (KPMP). https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-022.html	\$1.3 million total funds	Letter of intent: 11/11/24 Proposal: 12/10/24
25.	Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-26-002	The Interactions Core will serve as focal point for establishing productive collaborations within the Urology Centers Programs and between these Programs and other NIDDK urology training and scientific efforts and the broader research and clinical communities all under the umbrella Collaborating for the Advancement of Interdisciplinary Research in Benign Urology (CAIRIBU) Program. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-002.html	Up to \$1 million per year, for up to 5 years	Letter of intent: 10/21/24 Proposal: 11/21/24
26.	KidneyX Sustainability Prize (HHS/ASN)	The KidneyX Sustainability Prize seeks innovations to reduce water or power usage during dialysis care. This challenge aims to seize opportunities for sustainability by identifying and supporting solutions to reduce the resource demands of maintenance dialysis. The KidneyX Sustainability Prize anticipates that those solutions will help drive meaningful change in the sustainability of kidney care. https://www.challenge.gov/?challenge=kidneyx-sustainability-prize	Total prizes of \$7.25 million	Proposal: 10/30/24
		ENERGY SCIENCE (1)		
27.	FY24 Scale-Up of Integrated Biorefineries (DoE) DE-FOA-0003371	This FOA seeks applications to address the scale-up of promising technical pathways that produce cost-effective biofuels for aviation, marine, rail, off-road vehicle and heavy-duty trucks, and renewable chemicals. This FOA will fund the development, testing, and verification at engineering scale, of new technology and feedstock pathways for integrated biorefineries to reduce technology uncertainty through cost-shared pilot- and demonstration-scale biorefinery projects with industry. https://www.grants.gov/search-results-detail/356393	Up to \$3 million	Concept paper: 11/7/24 Full proposal: 1/16/25
		GENOMICS (1)		
28.	Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed) (NIH/ORIP) PAR-24-305	The goal of the Centers is to support collaborative research projects that bridge current personalized medicine efforts in human subjects with advances in animal genomics and genetic manipulation technologies, including the creation of interspecies somatic hybrids. By functionally linking these areas of research, the Centers aim to enhance the predictive value of preclinical studies through the use of precision animal models. https://grants.nih.gov/grants/guide/pa-files/PAR-24-305.html	Up to \$1.25 million per year, for up to 5 years	Proposal: 12/16/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (4)		
29.	Forecast: Complement-ARIE New Approach Methodologies (NAMs) Data Hub and Coordinating Center (U24 Clinical Trial Optional) (NIH Common Fund) NOT-RM-24-015	Complement-ARIE is expected to significantly advance understanding of human health and disease by providing a range of mature and/or validated and standardized biomedical research models. Developing these models will require multi-disciplinary expertise spanning in vitro, in silico and in chemico approaches focused on modeling and understanding human diseases and conditions, personalized medicine, environmental science, and in screening therapeutics for safety and effectiveness and environmental compounds for health hazards. https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-015.html	Up to \$5 million per year	Estimated post date: 11/29/24 Estimated proposal date: 3/10/25
30.	NICHHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed) (NIH/NICHHD) PAR-24-301	This NOFO supports the continued operation, maintenance, and dissemination of unique knowledge, data, and/or bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. https://grants.nih.gov/grants/guide/pa-files/PAR-24-301.html	Up to \$1.75 million per year, for up to 5 years	Multiple deadlines; NOFO open through 9/25/27
31.	Youth Mental Health Narratives (CDC/NASA)	In this challenge, solvers will help extract information from narratives in the National Violent Death Reporting System to help researchers better understand, prevent, and treat youth mental health crises. In the Automated Abstraction track, solvers will apply machine learning techniques to automate extraction of existing factor variables. In the Novel Variables track, solvers will research new factor variables that could be used to advance youth mental health research. https://www.challenge.gov/?challenge=youth-mental-health-narratives	Up to \$18,000	Proposal: 11/21/24
32.	Forecast: NIH Data Sharing Index (S-index) Challenge (NIH/NEI)	The S-index Challenge aims to advance the NIH mission by actively promoting data sharing and developing a robust metric to reward exemplary data sharers. This initiative seeks to incentivize and recognize researchers who excel in making their data accessible, ultimately fostering a culture of openness and collaboration within the scientific community. https://www.challenge.gov/?challenge=nih-data-sharing-index-s-index-challenge	Up to \$500,000	Registration: 3/3/25 Proposal: 6/2/25
		HIV/AIDS (5)		
33.	Forecast: Social Determinants of Health (SDoH) and Quality of Care Contributors to Cancer Disparities in People with HIV (U01; Clinical Trial Optional) (NIH/NCI) NOT-CA-24-106	This NOFO will solicit applications seeking to better understand the role of social determinants of health (SDoH) in contributing to or exacerbating cancer disparities and inequalities for people with HIV (PWH) across the cancer care continuum. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-106.html	Up to \$500,000 per year	Estimated post date: 10/14/24 Estimated proposal date: 1/10/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
34.	NOSI: Basic and Translational Oral Health Research Related to HIV/AIDS (NIH/NIDCR) NOT-DE-25-038	This NOSI aims to encourage innovative and multi-disciplinary basic and translational research to elucidate the mechanisms of, and strategies for, addressing HIV pathogenesis, HIV-associated comorbidities, co-infections, and complications in the oropharyngeal cavity. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-25-038.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
35.	Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed) (NIH/NIDDK/ORWH) RFA-DK-25-021	This NOFO invites applications that are focused on developing, using, and/or improving cellular models that recapitulate critical aspects of normal human physiology, such as microphysiological systems, organoids, and other three-dimensional models, to explore the interaction of HIV with tissues and processes within NIDDK's mission areas. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-021.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 2/20/25 Proposal: 3/20/25
		MEDICAL COUNTERMEASURES (2)		
36.	Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) (NIH/NIAMS/NIAID) PA-25-093	This NOFO intends to support fundamental research that will contribute to basic understanding of skin injuries caused by chemicals that have been identified as public health threats, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for medical countermeasure development. https://grants.nih.gov/grants/guide/pa-files/PA-25-093.html	Up to \$450,000, for up to 3 years	Multiple deadlines; NOFO open through 1/8/28
37.	Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-067	This NOFO supports early to mid-stage research focused on development of alternative human models of acute and/or delayed radiation-induced injuries (extracorporeal systems) to elucidate mechanisms of injury and to test medical countermeasures to treat and/or mitigate these injuries. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-067.html	Up to \$350,000 per year, for up to 5 years	Letter of intent: 1/6/25 Proposal: 2/6/25
		MENTAL HEALTH (2)		
38.	Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional) (NIH/NIMH) RFA-MH-25-200	This NOFO solicits applications from scientific hubs to support learning health care research in clinics offering evidence-based Coordinated Specialty Care (CSC) to persons in the early stages of psychotic illness. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-200.html	Up to \$1 million per year, for up to 4 years	Letter of intent: 1/3/25 Proposal: 2/3/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
39.	Forecast: Improving Mental and Behavioral Health Topical PCORI Funding Announcement -- Cycle 1 2025 (PCORI)	<p>This opportunity aims to fund studies comparing two or more approaches for prevention, diagnosis, treatment or care delivery related to mental and behavioral health conditions. Studies should address a critical clinical or care delivery problem. SAEs include: Mental and behavioral health of children and youth; Suicide prevention and crisis response; Strategies to improve mental health care access and delivery.</p> <p>https://www.pcori.org/funding-opportunities/announcement/improving-mental-and-behavioral-health-topical-pcori-funding-announcement-cycle-1-2025</p>	Up to \$12 million, for up to 5 years	System opens: 12/3/24 Letter of intent: 1/14/25 Proposal: 5/6/25
		MICROBIOME RESEARCH (1)		
40.	Predictions for Real-time Optimization of MICRObiomes of Built Environments (PRO-MICROBE) (ARPA-H) ARPA-H-MAI-24-01-06	<p>By creating new ways to assess and predict the impact of indoor microbial communities on occupant health outcomes, PRO-MICROBE seeks to transform how building design and engineering can support microbial communities important for optimal human health while resisting the colonization of pathogenic microorganisms.</p> <p>https://sam.gov/opp/06679fafce184ee784bdcabee9624a22/view</p>	Dependent upon proposal and award mechanism	Proposal: 11/4/24
		RARE DISEASES (1)		
41.	Draft: Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ARPA-H) ARPA-H-MAI-24-01-07	<p>The DECIDE ET endeavors to produce tools and technology that enable accelerated evaluation and validation of GMP for small batch therapies by demonstrating product quality and consistency that is commensurate with the amount of therapy that needs to be produced. By creating quantitative method(s) to dynamically inform the number of required batches, DECIDE seeks to ensure access to critical therapeutic solutions for Americans and provide a revolutionary pathway to address market failures by innovating approaches to right-size cell therapy production for pediatric rare disease.</p> <p>https://sam.gov/opp/4b1c2b83a0af401ba57e0e89e78c9b10/view</p>	Dependent upon proposal and award mechanism	Estimated post date: 10/22/24 Proposal: 11/18/24
		REGULATORY SCIENCE (1)		
42.	FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (HHS/FDA) FDABAA-25-00123	<p>The goal of this regulatory science framework is to harness regulatory science research to accomplish the following three charges that directly align with FDA's mission, to:</p> <p>I. Modernize development and evaluation of FDA-regulated products; II. Strengthen post-market surveillance and labeling of FDA-regulated products; III. Invigorate public health preparedness and response of the FDA, patients, and consumers.</p> <p>https://sam.gov/opp/c3e35e83134c40e5b96dde9c65f5c23a/view</p>	Dependent upon proposal and available funds	Optional early concept paper: 11/8/24 Industry day: 11/14/24 Proposal: 2/24/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (4)		
43.	DHA 2024.3 Small Business Innovation Research (SBIR) (DoD/DHA) DoD SBIR 24.3	This SBIR cycle includes topics such as: DHA243-001 Vaccine Delivery Vehicle for the Sustained Release of an HIV Vaccine and DHA243-002 Nanoparticle-based Drug Delivery Platform(s) for Traumatic Brain Injury. https://www.dodsbirsttr.mil/topics-app/?baa=DOD_SBIR_2024_P1_C3	Up to \$250,000, for 6 months (Phase I) Up to \$1.3 million, for up to 2 years (Phase II)	Proposal: 10/16/24
44.	DoD Small Business Technology Transfer 24.C (DoD) DoD STTR 24.C	This STTR cycle includes topics such as: DHA24C-001 3D Printed Synthetic Soft Tissue; CBD24C-T001 Cost Effective Synthesis and Processing of Novel Porous Organic Polymers for Protective Applications; and SF24C-T001 Community Cultures Biomanufacturing for Sustainable Space Defense. https://www.dodsbirsttr.mil/topics-app/?baa=DOD_STTR_2024_P1_CC	Up to \$250,000, for 6 months (Phase I) Up to \$1.3 million, for up to 2 years (Phase II)	Proposal: 10/16/24
45.	Forecast: NHLBI SBIR Phase IIB Small Market and Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) (NIH/NHLBI/NCATS) NOT-HL-24-030 NOT-HL-24-030	This NOFO will invite SBCs to submit Phase IIB grant applications to support later stage research and development for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance. Products submitted to the NHLBI should address a rare disease or young pediatric populations. NCATS intends to support applications: to develop innovations that reduce, remove or bypass costly and time-consuming bottlenecks in the translational science process; to speed the development and delivery of new drugs; diagnostics, medical devices and behavioral interventions to patients; and that address rare diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-030.html https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-031.html	Up to \$3.5 million	Estimated post date: 11/26/24 Estimated proposal date: 2/25/25
		SUBSTANCE USE DISORDER (16)		
46.	Forecast: Accelerating the Pace of Substance Use Research Using Existing Data (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA) NOT-DA-24-046 (R01) NOT-DA-24-047 (R21)	Existing data provide unique opportunities to better understand interactions between intrapersonal and environmental factors and substance use and disorder, as well as factors related to disease patterns and progressions, and variations in response to preventive interventions and substance use disorder treatment and HIV services utilization. Studies using these data might better describe, discriminate, and predict the complex, relapsing nature and course of substance use and disorder. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-046.html (R01) https://grants.nih.gov/grants/guide/notice-files/NOT-DA-24-047.html (R21)	TBD	Estimated post date: 12/1/24 Estimated proposal date: 6/17/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
47.	NOSI: Consequences of Prenatal Fentanyl Exposure (NIH/NIDA) NOT-DA-26-003	The purpose of this NOSI, with 7 linked grants, is to promote research on neurobehavioral, neurological, and potential teratogenic effects of prenatal fentanyl exposure in humans and in animal models. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-26-003.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/28
48.	Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) (NIH/NIDA) PAR-24-297	This NOFO encourages R03 applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. https://grants.nih.gov/grants/guide/pa-files/PAR-24-297.html	Up to \$150,000, for up to 1 year	Multiple deadlines; NOFO open through 1/7/28
49.	Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) (NIH/NIDA) PAR-24-298	This NOFO will support pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services. https://grants.nih.gov/grants/guide/pa-files/PAR-24-298.html	Up to \$275,000, for up to 2 years	Multiple deadlines; NOFO open through 9/9/27
50.	Behavioral & Integrative Treatment Development Program (R01/R34 Clinical Trial Optional) (NIH/NIDA) PAR-24-299 (R01) PAR-24-300 (R34)	These NOFOs encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, misuse, and dependence. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments. https://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-300.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to \$450,000, for up to 3 years (R34)	Letter of intent: 2/5/25 Proposal: 3/5/25
51.	Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01/R21 Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-26-009 (R01) RFA-DA-26-010 (R21)	These NOFOs promote research investigating protective and pathogenic mechanisms at the nexus of mitochondria function and aging in the context of HIV infection, antiretroviral therapy (ART) and exposure to addictive substances. We anticipate this foundational knowledge could be leveraged to develop targeted therapies and improve outcomes in people aging with HIV, substance use and addiction. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-009.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-010.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 3/10/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
52.	Remote Assessments of Substance Use Disorder (SUD)- Relevant Measurements (NIH/NIDA)	This Challenge solicits submissions of remote assessment methodologies and technologies currently being used to collect measurements relevant to SUD. These measurements include patient reported outcomes, physiological and biological measures, cognitive task performance, behavioral and social measures, and environmental characterizations. https://www.challenge.gov/?challenge=nida-remote-monitoring-1	Up to \$150,000	Proposal: 1/15/25
		THERAPEUTICS (2)		
53.	Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-065	This NOFO will support milestone-driven, early-stage translational research focused on drug discovery and development of novel therapeutics against select fungal pathogens including: <i>Candida</i> species, specifically <i>Candida auris</i> ; <i>Aspergillus fumigatus</i> ; <i>Coccidioides</i> ; and <i>Mucorales</i> . https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-065.html	Up to \$275,000, for up to 2 years (R21) Up to \$300,000 per year, for up to 3 years (R33)	Letter of intent: 12/28/24 Proposal: 1/28/25
54.	HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) (NIH) RFA-NS-25-023	This NOFO aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-023.html	Up to \$350,000 per year, for up to 3 years	Multiple deadlines; NOFO open through 1/15/27
		VISION HEALTH (1)		
55.	NEI Expand OHDSI Initiative for Eye Care and Ocular Imaging Challenge (NIH/NEI)	This Challenge aims to expand the OHDSI network for vision research by incentivizing researchers to submit innovative ideas for leveraging the network. Participants will be rewarded for their contributions, encouraging their organizations to adopt the OHDSI Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Expanding the network will enable the generation of valuable insights and drive advancements in patient care and outcomes in clinical ophthalmology and optometry. While winning entities are not required to, they are encouraged to use awards from this Challenge to integrate into the network, further fostering collaboration and cohesion within the OHDSI community. https://www.challenge.gov/?challenge=nei-expand-ohdsi-initiative-for-eye-care-and-ocular-imaging-challenge	Up to \$250,000	Registration: 11/12/24 Proposal: 1/31/25





Recurring Opportunities

October 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
56.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions. https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
57.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
58.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations. https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
59.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (3)		
60.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25
61.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
62.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
63.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
64.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
65.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
66.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
67.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
68.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9ecec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
69.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
70.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
71.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view	Dependent upon proposal	Proposal: 9/25/28
72.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for two AOIs: AOI #17: Digital MCMs and AOI #24: RePAIR. https://sam.gov/opp/a01f0468716d4a6f82befdc0838c8d77/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
73.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/5fff3c4c76c341a4a6b1d2010211c793/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/10/25
74.	Defense Sciences Office, Office-wide HR001124S0039	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/3c1dea286b74897bed07f3eefb446a0/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
75.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
76.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
77.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
78.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
79.	FY 2025 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003432	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/356590	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/25
		NATIONAL SCIENCE FOUNDATION (2)		
80.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program topics support the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis through 3/5/25
81.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to \$1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 3/5/25. Proposal: 11/6/24
		NAVY (3)		
82.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/work-with-us/funding-opportunities/fy25-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY		
83.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24
84.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
85.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

October 10, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

